Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple MyelomaJesús F. San Miguel, Hermann Einsele, Binod Dhakal et al.|New England Journal of Medicine|2023Cited by 719
International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disordersJens Hillengaß, Suzanne Lentzsch, Juan Du et al.|The Lancet Oncology|2019Cited by 493
Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working GroupPhilippe Moreau, Jean‐Luc Harousseau, Shaji Kumar et al.|The Lancet Oncology|2021Cited by 266
Activity of bortezomib in adult de novo and relapsed acute myeloid leukemia.Lidia Gil, Mariusz Wysocki, Jan Styczyński et al.|PubMed|2008Cited by 27
Prognostic factors and long-term outcome of autologous haematopoietic stem cell transplantation following a uniform-modified BEAM-conditioning regimen for patients with refractory or relapsed Hodgkin lymphoma: a single-center experienceAnna Czyż, Mieczysław Komarnicki, Anna Łojko‐Dankowska et al.|Medical Oncology|2013Cited by 22